Lv1
40 积分 2025-06-24 加入
Preoperative chemotherapy in operable breast cancer
1个月前
已完结
Pathological complete response and long-term clinical benefit in breast cancer: the CTNeoBC pooled analysis
1个月前
已完结
Evaluation of pathological complete response as surrogate endpoint in neoadjuvant randomised clinical trials of early stage breast cancer: systematic review and meta-analysis
1个月前
已完结
Surrogacy of Pathologic Complete Response in Trials of Neoadjuvant Therapy for Early Breast Cancer
1个月前
已完结
Breast Cancer Treatment
2个月前
已完结
Trastuzumab Deruxtecan after Endocrine Therapy in Metastatic Breast Cancer
6个月前
已完结
NCCN Task Force Report: Breast Cancer in the Older Woman
8个月前
已完结
Safety, pharmacokinetics, and antitumour activity of trastuzumab deruxtecan (DS-8201), a HER2-targeting antibody–drug conjugate, in patients with advanced breast and gastric or gastro-oesophageal tumours: a phase 1 dose-escalation study
8个月前
已完结
Trastuzumab deruxtecan versus treatment of physician's choice in patients with HER2-positive metastatic breast cancer (DESTINY-Breast02): a randomised, open-label, multicentre, phase 3 trial
8个月前
已完结
Trastuzumab Deruxtecan in Low or Ultralow HER2 Metastatic Breast Cancer
8个月前
已完结
皖公网安备34019202002308
